ALK | Allergy solutions for life

Celebrating the past and future of allergy solutions for life


Pioneers in helping people with allergies

For 100 years, ALK has consistently devised and developed major advances for the treatment of allergy


  • Post date
    ALK upgrades its full-year revenue and earnings outlook
  • Post date
    ALK provides update on regulatory process for the house dust mite allergy tablet in China
  • Post date
    ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
  • Post date
    ALK launches new growth strategy and 2028 financial ambitions
  • Post date
    ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review
  • Post date
    Listen in on ALK’s Capital Markets Day on 4 June 2024
  • Post date
    Three-month interim report (Q1) 2024 (unaudited) 
  • Post date
    ALK upgrades its full-year revenue outlook
  • Post date
    Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024
ALK Corporate Strategy 2024-2028
As the pioneers of allergy solutions, we are stepping into the next 100 years with a mission to help more people, with more solutions, more efficiently. We call it Allergy+.
100 Years of Pioneering Allergy Solutions
A new book has been written about ALK’s fascinating development in the field of allergy
The hunt for a vaccine – a podcast in five episodes
A fascinating story about ALK and the company’s 100 years of hunting allergy vaccines have been turned into a captivating podcast.

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.